Alector's second quarter arrived two steps into a pivot it did not choose. In less than a year the company's entire clinical pipeline collapsed on its own readouts - latozinemab failed its Phase 3 INFRONT-3 trial in October 2025, and GSK halted the co-developed nivisnebart on interim futility last April. Then, days after the quarter closed, the partner that had funded it all formalized the exit: GSK delivered written termination notice on July 6, effective January 2, 2027, capping a $700 million upfront collaboration that built and then abandoned both late-stage programs. What is left to value is not a fading pipeline but a deliberate re-platforming - the Alector Brain Carrier (ABC), a transferrin-receptor blood-brain-barrier delivery technology the company is now pointing at three drug modalities and a handful of preclinical programs.
The financial quarter tells a consolidation story, not a collapse story. Collaboration revenue fell to $3.3 million from $7.9 million a year ago as the GSK work winds down, R&D costs shrank to $19.5 million on the workforce reduction, and the net loss narrowed to $23.0 million from $30.5 million - $0.21 a share versus $0.30. Cash, equivalents and marketable securities stood at $172.8 million at June 30, down from $256.0 million at year-end, a roughly $83 million first-half draw. Management says that runway funds operations at least through 2027. What this quarter really establishes is the shape of the bet now: at about $2.09 a share, the market capitalization near $233 million leaves an enterprise value of roughly $60 million on top of cash - a price for an un-validated platform and an early anti-amyloid antibody, with the cash balance funding them. The question the report answers is whether that low multiple is a bargain on an under-appreciated BBB delivery asset or a discount to uncertainty on a company that has already bet and lost its first two.